Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors

Majdoub, Faycal El; Neudorfer, Clemens; Blau, Tobias; Hellmich, Martin; Bührle, PD Christian; Deckert, Martina; Sturm, Volker; Maarouf, PD Mohammad

doi:10.1007/s00066-015-0887-2

Cited by 6 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is an overall complication rate that includes not only severe, but all complications and covers not only the periprocedural time, but the entire follow-up period. Severe complications (radionecrosis, local cerebral bleeding, cerebritis) occurred in 6% of cases, which is in line with other brachytherapy studies [ 11 , 25 ]. Comparison with other radiotherapy methods (e.g.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

et al. 2020

View full text Add to dashboard Cite

Background This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. Methods This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. Results For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). Conclusion SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Ten-years OS and PFS rates as high as 89.8% and 47.3% have been reported for a combination treatment of SBT and EBRT in oligodendroglial brain tumors WHO grade II [ 25 ]. In our patient cohort only 16 specimens were classified as oligoastrocytoma or oligodendroglioma, known to be favorable histologies.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Hier hat sich die Anwendung der interstitiellen Radiochirurgie mit einer stereotaktischen Implantation von Jod-125-Seeds als sehr sicher und hocheffektiv erwiesen. Diese Methode wird auch Brachytherapie genannt und wurde von Neurochirurgen in den 1950er Jahren entwickelt [9][10][11]. In Österreich bin ich der einzige Neurochirurg, der diese Methode beherrscht.…”

Section: Elektrische Hirnstimulation Zur Lokalisation Des Kortikalen unclassified

Stellenwert der Neuromodulation bei Funktionsstörungen der Hand

Eisner

2019

Manuelle Medizin

View full text Add to dashboard Cite

Low dose rate permanent seed brachytherapy: tracing its evolution and current status

Banerjee

Kataria

Goyal

et al. 2020

Precision Radiation Oncology

View full text Add to dashboard Cite

A recent surge in publications on low dose rate permanent seed brachytherapy prompted us to review the currently available literature in order to provide a summary of the therapy. To this end, we composed a comprehensive review on the available English language publications in PubMed, EMBASE, and Google Scholar. The general principles of seed brachytherapy are discussed, along with radiobiology and technical aspects. Seed brachytherapy has been increasingly used in various sites for primary treatment, and is considered to be particularly useful in cases of reirradiation and otherwise untreatable malignancies. In recent decades, there have been considerable advances in the technology used in seed brachytherapy, including steps to prevent the migration of seeds, reduce personnel exposure to radiation, and use of sophisticated 3-D planning for better dosimetric results, which have ultimately translated into better clinical outputs. Technical advances in seed brachytherapy have lagged behind those in external beam radiotherapy and high dose rate brachytherapy; however, there is renewed interest due to encouraging clinical results in the primary setting, as well as reirradiation for recurrent disease across several sites.

show abstract

Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors

Cited by 6 publications

References 44 publications

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

Stellenwert der Neuromodulation bei Funktionsstörungen der Hand

Low dose rate permanent seed brachytherapy: tracing its evolution and current status

Contact Info

Product

Resources

About